Cargando…
Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors
Initially developed as glucose-lowering drugs, sodium-glucose co-transporter type 2 inhibitors (SGLT2i) have demonstrated to be effective agents for the risk reduction of cardiovascular (CV) events in patients with type 2 diabetes mellitus (T2DM). Subsequently, data has emerged showing a significant...
Autores principales: | Margonato, Davide, Galati, Giuseppe, Mazzetti, Simone, Cannistraci, Rosa, Perseghin, Gianluca, Margonato, Alberto, Mortara, Andrea |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895775/ https://www.ncbi.nlm.nih.gov/pubmed/32901315 http://dx.doi.org/10.1007/s10741-020-10024-2 |
Ejemplares similares
-
Nonalcoholic Fatty Liver Disease, Liver Fibrosis and Cardiovascular Disease in the Adult US Population
por: Ciardullo, Stefano, et al.
Publicado: (2021) -
Compassionate use of ruxolitinib in patients with SARS‐Cov‐2 infection not on mechanical ventilation: Short‐term effects on inflammation and ventilation
por: Mortara, Andrea, et al.
Publicado: (2021) -
Heart Failure With Mid-range or Recovered Ejection Fraction: Differential Determinants of Transition
por: Margonato, Davide, et al.
Publicado: (2020) -
Short‐term echocardiographic evaluation by global longitudinal strain in patients with heart failure treated with sacubitril/valsartan
por: Mazzetti, Simone, et al.
Publicado: (2020) -
NT-ProBNP and mortality across the spectrum of glucose tolerance in the general US population
por: Ciardullo, Stefano, et al.
Publicado: (2022)